{"entity":{"id":"drug-response-sensitivity","kind":"term","name":"Drug response and drug sensitivity (IC50, AUC)","aka":["drug sensitivity","drug response prediction","cell-line drug sensitivity","IC50","half maximal inhibitory concentration","dose-response AUC","area under the dose-response curve","GI50","AAC"],"tldr":"Drug sensitivity is how strongly a tumour or cell line is held back by a compound; it is summarised by the concentration that halves growth (IC50) or by the area under the whole dose-response curve.","summary":"The half maximal inhibitory concentration, IC50, measures the potency of a substance in inhibiting a biological function, the amount needed to inhibit a process by half in vitro (Wikipedia). Cell-line screens such as GDSC and CTRP report IC50, GI50 and the area under (or above) the dose-response curve for hundreds of drugs across hundreds of lines. The readouts are not interchangeable: different viability assays (CellTiter-Glo versus Syto60) and different summary statistics are a known source of disagreement between datasets.","asOf":"2026-09-24","wikipedia":"https://en.wikipedia.org/wiki/IC50","links":[{"label":"Yang et al., GDSC: a resource for therapeutic biomarker discovery in cancer cells (Nucleic Acids Research 2013)","url":"https://doi.org/10.1093/nar/gks1111"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/IC50"}],"tags":["cansim-terms"],"related":["depmap","cancer-ai-vocabulary"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pharmacogenomics-term","cell-lines-as-proxy"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Listed in the CanSim terms map 1.0.0 (docs/onco/terms.json, generated 2026-09-24), CC BY 4.0, attribution: CanSim project, an open, public-data-first cancer foundation-model programme; CanSim page path /terms/drug-response."],"provenance":{"editedBy":"OnCo CanSim terms wave (Wikipedia summaries, standards and project pages, GDC and FDA pages, Europe PMC)","editedOn":"2026-09-24","note":"CanSim terms map 1.0.0 (docs/onco/terms.json, generated 2026-09-24), CC BY 4.0, attribution: CanSim project, an open, public-data-first cancer foundation-model programme"},"category":"Biomarkers"},"route":"/terms/drug-response-sensitivity/","neighbours":{"collection":[{"id":"depmap","kind":"collection","name":"DepMap (Cancer Dependency Map)","route":"/collections/depmap/"}],"term":[{"id":"cancer-ai-vocabulary","kind":"term","name":"Cancer AI vocabulary (CanSim terms map)","route":"/terms/cancer-ai-vocabulary/"},{"id":"cell-lines-as-proxy","kind":"term","name":"Cell lines as a proxy for patients","route":"/terms/cell-lines-as-proxy/"},{"id":"drug-response-splits","kind":"term","name":"Drug-response data splits: leave-cell-line-out, leave-drug-out, leave-tissue-out","route":"/terms/drug-response-splits/"},{"id":"pharmacogenomics-term","kind":"term","name":"Pharmacogenomics","route":"/terms/pharmacogenomics-term/"}]}}